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istening to Patients*
dward P. Havranek, MD, FACC,†‡
arry A. Allen, MD, MHS‡
enver, Colorado
he paper by Stevenson et al. (1) in this issue of the Journal
s, on first reading, an interesting report on how patients
ith advanced heart failure report their priorities for quality
ersus quantify of life using an arcane questionnaire called
he time trade-off (TTO). On closer reading, however, the
aper is much more than that. It is a call for cardiologists
nd patients to change the way they discuss choices about
herapy.
See page 1702
To understand how the results of this paper relate to
veryday practice, some background about the concept
easured by the TTO task—utility—is needed. A utility is
quantification of the strength of an individual person’s
reference for the possible outcomes of a decision. Although
he primacy of preference in decision making has been
romoted since at least the 19th century by philosophers
uch as John Stuart Mill, a quantitative way to measure
reference when the outcomes of the decision are uncertain
as first described by the mathematician John Von Neu-
ann and the economist Oskar Morgenstern in 1944 as
art of the foundation of game theory (2). This conceptu-
lization of utility has subsequently been used widely in
conomics and public policy, but medical applications have
een limited.
In a medical context, a utility measures the value an
ndividual patient places on his or her current state of
ealth. Based on theoretical considerations, utility is best
easured with a set of questions called the standard gamble,
n which a subject is asked to choose between accepting his
r her current state of health and undergoing a procedure
hat can result in either death or perfect health. The risk of
eath associated with the procedure is varied until the
ubject is indifferent in a choice between current health state
nd taking a chance on the procedure. The TTO method,
ell described in the paper by Stevenson et al. (1), was
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.p
From the †Denver Health Medical Center and ‡University of Colorado, Denver,
olorado.eveloped as an alternative to the standard gamble specifi-
ally for use in medical applications. Instead of being asked
o choose between current health and a chance at perfect
ealth, respondents are asked to choose between a length of
ime in current health and a shorter time in perfect health;
he length of time in perfect health is varied until the subject
ecomes indifferent. It seems to be more easily interpreted
y clinicians and patients, and gives results quantitatively
imilar to the standard gamble. Utility for health states can
lso be measured using multi-attribute questionnaires such
s the European Quality of Life, 5-Dimension survey (3)
nd the Health Utilities Index (4), but their scoring is based
n a correlation of standard gamble or TTO results from
ommunity subjects with questionnaire results.
Within the context of performing a prospective random-
zed trial (ESCAPE [Evaluation Study of Congestive Heart
ailure and Pulmonary Artery Catheter Effectiveness])
valuating tailored therapy based on hemodynamic mea-
urements in patients with advanced heart, Stevenson et al.
1) had the foresight to incorporate survival preference
uestions into data collection. Utilities were measured by
TO at baseline, 3-month follow-up, and 6-month follow-
p. As pointed out by the authors, baseline TTO values
ere similar to those obtained with this instrument in prior
tudies of patients with heart failure (5–7). They found a
imodal distribution of survival preferences. Approximately
ne-half of the patients expressed a preference for survival
ains over improved health, and approximately one-fourth
f the patients expressed a preference for much shorter
urvival but with better health; the remaining one-fourth of
atients fell somewhere in the middle. In general, patients
ith more severe heart failure were willing to trade longer
urvival for better health, but illness severity predicted
references poorly for individual patients. In measuring
TO over time, the current study goes a step further than
rior studies, and provides us with a number of unique
nsights.
First, patients became more likely to value survival over
etter health during the transition from acute illness requiring
ospitalization (baseline) to chronic illness managed in the
utpatient setting (3-month follow-up). These preference
hanges mirrored the marked resolution in global well-being
nd symptom scales that occurred in the ESCAPE study
egardless of treatment assignment (8).
Second, in the 6 months after the inpatient-outpatient
ransition, patient preferences remained remarkably stable.
n aggregate, TTO measurements changed only 4% during
ong-term follow-up from 3 to 6 months. Thus, clinicians
an be confident that measured preferences reflect, in part,
haracteristics intrinsic to patients and are a reliable basis for
ecision making.
The authors went on to assess the relationship between
urvival and preference for survival over better health.
ne-third of patients who survived 3 months had ex-ressed willingness to trade away 90% of their remaining
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Listening to Patients November 18, 2008:1709–10ime for better health, compared with only 6% of those
atients surviving through 6-month follow-up.
Although the study has limitations of an unfamiliar end
oint, missing data, and a narrow range of illness studied,
one of these limitations changes the fact that the paper
ontains insights that are immediately useful to clinicians.
First, although patient beliefs, attitudes, and preferences
enerally align with those of physicians, they may be
nexpectedly different in a substantial minority and must
herefore be elicited explicitly. In the current study, patients
illing to trade away a substantial proportion of survival did
ot differ significantly from other patients in regard to age,
ender, ejection fraction, renal function, or blood pressure.
hese findings mirror those of a recent study in which heart
ailure patients, on average, overestimated their life expect-
ncies by approximately 40% irrespective of disease severity
r future survival (9). To elicit preferences, physicians must
rst have accurate knowledge not only of expected survival
ssociated with therapy, but also of effects of therapy on
uality of life. Unfortunately, many clinical trials of heart
ailure therapy have not provided us with data adequate to
nform patients about expectations regarding quality of life.
Second, it is important that discussions with patients
bout their preferences take place when they are in a stable
ondition after acute exacerbations, as outlook seems to
hange importantly after hospitalization.
Thus, 2 patients meeting the same indications for an
mplantable cardioverter-defibrillator might make different
ecisions about implantation knowing that the device will
rolong survival without improving their current state of
ealth, and these patients may be indistinguishable by
emographic or clinical characteristics. A patient who re-
uses an implantable cardioverter-defibrillator during hos-
italization for an acute exacerbation might make a different
nformed decision if presented with the choice a few weeks
ater as an outpatient. Similar considerations apply to other
ommon decisions with which clinicians and patients with
eart failure are faced, such as decisions regarding coronary
rtery bypass surgery for patients with ischemic cardiomy-
pathy or mechanical circulatory support for patients failing
K
hore conservative therapies. Recent calls have been made to
egin incorporating patient preferences into national guide-
ines (10).
Simply put, we must ask patients with advanced heart
ailure how their current lives intersect with how they view
eath. Although some may be unable to answer, if we listen
o those that do answer, we are likely to hear wisdom and
ourage we might otherwise have missed. Such insight is
ertain to help us better tailor care to the individual patients
e treat.
eprint requests and correspondence: Dr. Edward P. Havranek,
enver Health Medical Center #0960, 777 Bannock Street,
enver, Colorado 80204-4507. E-mail: ehavrane@dhha.org.
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